# OPTIMIZE IDE for the Treatment of ACS

Study · id `cardio:ct-nct03190473` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03190473](<https://clinicaltrials.gov/study/NCT03190473>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT03190473

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 1630 participants.

## Technical summary

Registry record NCT03190473. Randomized; single masking; primary purpose treatment. Start 2018-01-02 (actual); primary completion 2020-07-17 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 1630 participants (enrolled count; ClinicalTrials.gov record NCT03190473, source copy `cardio:ctgov-nct03190473-2023-03-23`, retrieved 2026-10-31)
- Started: 2018-01-02 (actual) (ClinicalTrials.gov record NCT03190473, source copy `cardio:ctgov-nct03190473-2023-03-23`, retrieved 2026-10-31)
- Primary completion: 2020-07-17 (actual) (ClinicalTrials.gov record NCT03190473, source copy `cardio:ctgov-nct03190473-2023-03-23`, retrieved 2026-10-31)
- Completion: 2023-03-08 (actual) (ClinicalTrials.gov record NCT03190473, source copy `cardio:ctgov-nct03190473-2023-03-23`, retrieved 2026-10-31)
- Countries: United States; Japan; Netherlands (ClinicalTrials.gov record NCT03190473, source copy `cardio:ctgov-nct03190473-2023-03-23`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03190473-2023-03-23`, retrieved 2026-10-31)

## The registry's words

- Brief title: OPTIMIZE IDE for the Treatment of ACS
- Acronym: OPTIMIZE
- Condition: Acute Coronary Syndrome
- Intervention (Device): DES
- Lead sponsor: Svelte Medical Systems, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Drug-eluting stent (`cardio:drug-eluting-stent`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Safety and Effectiveness of the SVELTE Fixed-Wire and Rapid Exchange Bioresorbable-Polymer Sirolimus-Eluting Coronary Stent Systems for the Treatment of Atherosclerotic Lesions: Results of the OPTIMIZE Randomized Study (`cardio:pubmed-34353122`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: dc7bb9db9ac6fe933b5e30d16a200765cda4c425257ed771acaa2dd7a88df753
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
